Research: 2000–2010

See also: Research: 2011–present | By symptom | Reviews & meta-analyses | Related research
A research briefing summarizes two recent systematic reviews/meta-analyses.

📚 = systematic review / meta-analysis      🧬 = genetics focus      🐀 = animal study

Jump to:
2011–present | 2010 | 2008 | 2006 | 2004 | 2002 | 2000 | Early research (1974–1999)

2010

↑ back to top

🐀 Darbra S, Pallarès M. Alterations in neonatal neurosteroids affect exploration during adolescence and prepulse inhibition in adulthood. Psychoneuroendocrinology. 2010;35(4):525-535. doi:10.1016/j.psyneuen.2009.08.020 | PubMed

Dušková M, Hill M, Stárka L. The influence of low dose finasteride, a type II 5α-reductase inhibitor, on circulating neuroactive steroids. Horm Mol Biol Clin Investig. 2010 Jan 1;1(2):95-102. doi:10.1515/HMBCI.2010.010 | PubMed

Laborde E, Brannigan RE. Effect of 1-mg dose of finasteride on spermatogenesis and pregnancy. J Androl. 2010 Mar-Apr;31(2):e1-2. doi:10.2164/jandrol.109.009381 | PubMed | Wiley Free Access

Lynn R, Krunic A. Therapeutic hotline. Treatment of androgenic alopecia with finasteride may result in a high grade prostate cancer in patients: fact or fiction?. Dermatol Ther. 2010;23(5):544-546. doi:10.1111/j.1529-8019.2010.01358.x | PubMed

📚 Mella JM, Perret MC, Manzotti M, Catalano HN, Guyatt G. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol. 2010;146(10):1141-1150. doi:10.1001/archdermatol.2010.256 | PubMed

Moreno-Fernandez A, Mira Laguarda JM, Ruiz-Hornillos FJ, Rubio Sotes M. Urticarial rush due to finasteride. Allergy. 2010 Mar;65(3):405-6. doi:10.1111/j.1398-9995.2009.02165.x | PubMed

Ramot Y, Czarnowicki T, Zlotogorski A. Finasteride induced Gynecomastia: Case report and Review of the Literature. Int J Trichology. 2009;1(1):27–29. doi:10.4103/0974-7753.51930 | PubMed

Römer B, Gass P. Finasteride-induced depression: new insights into possible pathomechanisms [published correction appears in J Cosmet Dermatol. 2011 Mar;10(1):85]. J Cosmet Dermatol. 2010;9(4):331-332. doi:10.1111/j.1473-2165.2010.00533.x | PubMed

🐀 Römer B, Pfeiffer N, Lewicka S, et al. Finasteride treatment inhibits adult hippocampal neurogenesis in male mice. Pharmacopsychiatry. 2010;43(5):174-178. doi:10.1055/s-0030-1249095 | PubMed

Wong AC, Mak ST. Finasteride-associated cataract and intraoperative floppy-iris syndrome. J Cataract Refract Surg. 2011;37(7):1351‐1354. doi:10.1016/j.jcrs.2011.04.013 | PubMed

2009

↑ back to top

Anitha B, Inamadar AC, Ragunatha S. Finasteride-its impact on sexual function and prostate cancer. J Cutan Aesthet Surg. 2009;2(1):12-16. doi:10.4103/0974-2077.53093

🐀🧬 Duarte-Guterman P, Langlois VS, Hodgkinson K, et al. The aromatase inhibitor fadrozole and the 5-reductase inhibitor finasteride affect gonadal differentiation and gene expression in the frog Silurana tropicalis. Sex Dev. 2009;3(6):333-341. doi:10.1159/000280586 | PubMed

Dusková M, Hill M, Hanus M, Matousková M, Stárka L. Finasteride treatment and neuroactive steroid formation. Prague Med Rep. 2009;110(3):222-230. Journal site | PubMed

🐀 Kolasa A, Marchlewicz M, Kurzawa R, et al. The expression of inducible nitric oxide synthase (iNOS) in the testis and epididymis of rats with a dihydrotestosterone (DHT) deficiency. Cell Mol Biol Lett. 2009;14(3):511-27. doi:10.2478/s11658-009-0019-z | PubMed | PMC full text

🐀 Serga, CNK. The Effect of Different Doses of Finasteride on Sperm Morphology and Motility and Reactive Oxygen Species Concentrations in Rats. Med J Cairo Univ. Sept 2009;77(1):439–447. PDF on semanticscholar.org

Smith AB, Carson CC. Finasteride in the treatment of patients with benign prostatic hyperplasia: a review. Ther Clin Risk Manag. 2009;5(3):535–545. doi:10.2147/tcrm.s6195 | PubMed

🐀 Urbatzka R, Watermann B, Lutz I, Kloas W. Exposure of Xenopus laevis tadpoles to finasteride, an inhibitor of 5-alpha reductase activity, impairs spermatogenesis and alters hypophyseal feedback mechanisms. J Mol Endocrinol. 2009 Nov;43(5):209-19. doi:10.1677/JME-09-0058 | PubMed | Free access

🐀 Yawno T, Hirst JJ, Castillo-Melendez M, Walker DW. Role of neurosteroids in regulating cell death and proliferation in the late gestation fetal brain. Neuroscience. 2009;163(3):838-847. doi:10.1016/j.neuroscience.2009.07.009 | PubMed

2008

↑ back to top

Amory JK, Anawalt BD, Matsumoto AM, et al. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men. J Urol. 2008;179(6):2333-2338. doi:10.1016/j.juro.2008.01.145 | PubMed

Erdemir F, Harbin A, Hellstrom WJ. 5-alpha reductase inhibitors and erectile dysfunction: the connection. J Sex Med. 2008;5(12):2917-2924. doi:10.1111/j.1743-6109.2008.01001.x | PubMed

Hamdy FC, Rouprêt M. [The PCPT trial]. Prog Urol. 2008;18 Suppl 3:S40-3. doi:10.1016/S1166-7087(08)70512-8

🐀 Kolasa A, Marchlewicz M, Adler G, Ciechanowicz A, Głabowski W, Wiszniewska B. Expression of E-SOD, GPX5 mRNAs and immunoexpression of Cu/ZnSOD in epididymal epithelial cells of finasteride-treated rats. Andrologia. 2008 Oct;40(5):303-11. doi:10.1111/j.1439-0272.2008.00858.x | PubMed

Liu KE, Binsaleh S, Lo KC, Jarvi K. Propecia-induced spermatogenic failure: a report of two cases. Fertil Steril. 2008;90(3):. doi:10.1016/j.fertnstert.2007.08.026 | PubMed

Lombardo, R., Loraschi, A., Lecchini, S. et al. Finasteride-Associated Central Serious Chorioretinopathy. Drug Safety [Not indexed in PubMed]. 2008;31:885. doi:10.2165/00002018-200831100-00098

🐀 Martín-García E, Darbra S, Pallarés M. Neonatal finasteride induces anxiogenic-like profile and deteriorates passive avoidance in adulthood after intrahippocampal neurosteroid administration. Neuroscience. 2008;154(4):1497-1505. doi:10.1016/j.neuroscience.2008.04.062 | PubMed

🐀 Parivar K, Yaghmaei P, Sekhavati S. The role and effect of finasteride on the spermatogenesis, prostate gland and epididym of mature NMRI mouse in in vivo and in vitro conditions. Med Sci J Islam Azad Univ. 2008;179:2333-8. PDF at iautmu.ac.ir

Sarvis JA, Thompson IM. Prostate cancer chemoprevention: update of the prostate cancer prevention trial findings and implications for clinical practice. Curr Oncol Rep. 2008;10(6):529-532. doi:10.1007/s11912-008-0080-1 | PubMed

Wilt TJ, MacDonald R, Hagerty K, Schellhammer P, Kramer BS. Five-alpha-reductase Inhibitors for prostate cancer prevention. Cochrane Database Syst Rev. 2008;(2):CD007091. doi:10.1002/14651858.CD007091

2007

↑ back to top

Al Hammadi A, Asai Y, Patt ML, Sasseville D. Erythema annulare centrifugum secondary to treatment with finasteride. J Drugs Dermatol. 2007;6(4):460-463. PubMed

Amory JK, Wang C, Swerdloff RS, et al. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men [published correction appears in J Clin Endocrinol Metab. 2007 Nov;92(11):4379]. J Clin Endocrinol Metab. 2007;92(5):1659–1665. doi:10.1210/jc.2006-2203 | PubMed

Issa SA, Dagres E. Intraoperative floppy iris syndrome and finasteride intake. J Cataract Refect Surg. 2007;33:2142– 2143. doi:10.1016/j.jcrs.2007.07.025 | PubMed

Moinpour CM, Darke AK, Donaldson GW, et al. Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2007;99(13):1025-1035. doi:10.1093/jnci/djm023 | PubMed

Mondaini N, Gontero P, Giubilei G, et al. Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon? J Sex Med. 2007;4(6):1708-1712. doi:10.1111/j.1743-6109.2007.00563.x | PubMed

Naslund MJ, Miner M. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. Clin Ther. 2007;29(1):17-25. doi:10.1016/j.clinthera.2007.01.018 | PubMed

Yeu E, Grostern R. Saw palmetto and intraoperative floppy-iris syndrome. J Cataract Refract Surg. 2007 May;33(5):927-8. doi:10.1016/j.jcrs.2006.12.032 | PubMed

2006

↑ back to top

🐀 de Brito Faturi C, Teixeira-Silva F, Leite JR. The anxiolytic effect of pregnancy in rats is reversed by finasteride. Pharmacol Biochem Behav. 2006;85(3):569-574. doi:10.1016/j.pbb.2006.10.011 | PubMed

Carson CC. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both? BJU Int. 2006;97 Suppl 2:39-43; discussion 44-5. doi:10.1111/j.1464-410X.2006.06105.x

Finn DA, Beadles-Bohling AS, Beckley EH, et al. A new look at the 5alpha-reductase inhibitor finasteride. CNS Drug Rev. 2006;12(1):53-76. doi:10.1111/j.1527-3458.2006.00053.x

Giuliano F. Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int. 2006;97 Suppl 2:34-38; discussion 44-5. doi:10.1111/j.1464-410X.2006.06104.x

🐀 Mann PE. Finasteride delays the onset of maternal behavior in primigravid rats. Physiol Behav. 2006;88(4-5):333-338. doi:10.1016/j.physbeh.2006.04.008 | PubMed

Miner M, Rosenberg MT, Perelman MA. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function. Clin Ther. 2006;28(1):13-25. doi:10.1016/j.clinthera.2006.01.004

Rahimi-Ardabili B, Pourandarjani R, Habibollahi P, Mualeki A. Finasteride induced depression: a prospective study. BMC Clin Pharmacol. 2006;6:7. doi:10.1186/1472-6904-6-7 | PubMed

🐀 Robaire B, Henderson NA. Actions of 5alpha-reductase inhibitors on the epididymis. Mol Cell Endocrinol. 2006;250(1-2):190–195. doi:10.1016/j.mce.2005.12.044 | PubMed

Ryu HK, Kim KM, Yoo EA, Sim WY, Chung BC. Evaluation of androgens in the scalp hair and plasma of patients with male-pattern baldness before and after finasteride administration. Br J Dermatol. 2006;154(4):730‐734. doi:10.1111/j.1365-2133.2005.07072.x | PubMed

2005

↑ back to top

Djavan B, Milani S, Fong YK. Dutasteride: a novel dual inhibitor of 5alpha-reductase for benign prostatic hyperplasia. Expert Opin Pharmacother. 2005;6(2):311-317. doi:10.1517/14656566.6.2.311

🐀 Jia Y, Cue YG, Wang XD, Wang XH, Tong JS, Ma DZ, Cai RF, Di FS. [Effect of selective 5alpha-reductase inhibitor or/and testosterone undecanoate on the reproductive function of male rats]. Zhonghua Nan Ke Xue. 2005 Jan;11(1):38-41. Chinese. PubMed

Kaya C, Ozyurek M, Turkeri LN. Comparison of microvessel densities in rat prostate tissues treated with finasteride, bicalutamide and surgical castration: a preliminary study. Int J Urol. 2005 Feb;12(2):194-8. doi:10.1111/j.1442-2042.2005.01005.x | PubMed

Kuritzky L. Noninvasive management of lower urinary tract symptoms and sexual dysfunction associated with benign prostatic hyperplasia in the primary care setting. Compr Ther. 2005;31(3):194-208. doi:10.1385/comp:31:3:194

Marihart S, Harik M, Djavan B. Dutasteride: a review of current data on a novel dual inhibitor of 5alpha reductase. Rev Urol. 2005;7(4):203-210. PubMed

McVary KT. Sexual Function and α-Blockers. Rev Urol. 2005;7(Suppl 8):S3-S11. PubMed

Paick SH, Meehan A, Lee M, Penson DF, Wessells H. The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: results from the proscar long-term efficacy and safety study. J Urol. 2005;173(3):903-907. doi:10.1097/01.ju.0000152088.00361.a7

🐀 Ribeiro CM, Pereira OC. 5alpha-reductase 2 inhibition impairs brain defeminization of male rats: reproductive aspects. Pharmacol Biochem Behav. 2005;82(1):228-235. doi:10.1016/j.pbb.2005.08.015

Rosen RC, Giuliano F, Carson CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol. 2005;47(6):824–837. doi:10.1016/j.eururo.2004.12.013 | PubMed

🐀 Shen ZJ, Chen SW, Lu YL, et al. Preliminary study on androgen dependence of calcitonin gene-related peptide in rat penis. Asian J Androl. 2005 Mar;7(1):55-9. doi:10.1111/j.1745-7262.2005.00003.x | PubMed

📚 Thomson A. Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hyperplasia. Core Evid. 2005;1(2):143-156. PubMed

🧬 Wakisaka N, Taira Y, Ishikawa M, et al. Effectiveness of finasteride on patients with male pattern baldness who have different androgen receptor gene polymorphism. J Investig Dermatol Symp Proc. 2005;10(3):293-294. doi:10.1111/j.0022-202X.2005.10123.x | PubMed

Wang XD, Jia Y, Cui YG, Wang XH, Tong JS, Ma DZ, Cai RF, Di FS. [Effect of large-dosage of 5alpha-reductase inhibitors on the spermatogenesis of male rats]. Zhonghua Nan Ke Xue. 2005 Sep;11(9):652-4. Chinese. PubMed

2004

↑ back to top

Chou SY, Kao SC, Hsu WM. Propecia-associated bilateral cataract. Clin Exp Ophthalmol. 2004 Feb;32(1):106-8. doi:10.1046/j.1442-9071.2004.00770.x | PubMed

Glina S, Neves PA, Saade R, Netto NR Jr, Soares JB, Galuppo AG. Finasteride-associated male infertility. Rev Hosp Clin Fac Med Sao Paulo. 2004 Aug;59(4):203-5. doi:10.1590/s0041-87812004000400009 | PubMed

Klein EA, Thompson IM. Update on chemoprevention of prostate cancer. Curr Opin Urol. 2004;14(3):143-149. doi:10.1097/00042307-200405000-00002 | PubMed

Lechuga Sancho AM, Hernández Serrano R, González Casado I, Gracia Bouthelier R. Recién nacido con extrofia vesical y posible exposición intrauterina a finasterida [Newborn with bladder extrophy associated with finasteride exposure]. An Pediatr (Barc). 2004 Nov;61(5):451-3. doi:10.1016/s1695-4033(04)78429-5 | PubMed

Libecco JF, Bergfeld WF. Finasteride in the treatment of alopecia. Expert Opin Pharmacother. 2004 Apr;5(4):933-40. doi:10.1517/14656566.5.4.933 | PubMed

🐀 🧬 Liu XD, Li H, Bu H, et al. [Effects of finasteride on capillary in the ventral prostate of rat]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2004 Mar;35(2):226-8. Chinese. PubMed

Marks LS. 5alpha-reductase: history and clinical importance. Rev Urol. 2004;6 Suppl 9(Suppl 9):S11-21. PubMed

Pitts WR Jr. Finasteride (Propecia) and the promotion of high-grade prostate cancer. Arch Dermatol. 2004;140(7):885‐886. doi:10.1001/archderm.140.7.885-b | PubMed

Tosti A, Pazzaglia M, Soli M, et al. Evaluation of sexual function with an international index of erectile function in subjects taking finasteride for androgenetic alopecia. Arch Dermatol. 2004;140(7):857-858. doi:10.1001/archderm.140.7.857 | PubMed

2003

↑ back to top

Altomare G, Capella GL. Depression circumstantially related to the administration of finasteride for androgenetic alopecia. J Dermatol. 2002;29(10):665–669. doi:10.1111/j.1346-8138.2002.tb00200.x | PubMed

[Comment] Pope JE, Makela EH. Response to article “Depression circumstantially related to the administration of finasteride for androgenetic alopecia” (J Dermatol, 29, 665-669, 2002). J Dermatol. 2003;30(11):837–844. doi:10.1111/j.1346-8138.2003.tb00488.x | PubMed

🐀 Bowman CJ, Barlow NJ, Turner KJ, Wallace DG, Foster PM. Effects of in utero exposure to finasteride on androgen-dependent reproductive development in the male rat. Toxicol Sci. 2003;74(2):393-406. doi:10.1093/toxsci/kfg128

Carbone DJ, Hodges S. Medical therapy for benign prostatic hyperplasia: sexual dysfunction and impact on quality of life. Int J Impot Res. 2003;15(4):299-306. doi:10.1038/sj.ijir.3901017

Kassabian VS. Sexual function in patients treated for benign prostatic hyperplasia. Lancet. 2003;361(9351):60-62. doi:10.1016/S0140-6736(03)12164-2 | PubMed

Larson TR. Current treatment options for benign prostatic hyperplasia and their impact on sexual function. Urology. 2003;61(4):692-698. doi:10.1016/s0090-4295(02)02552-9

Lowe FC, McConnell JD, Hudson PB, et al. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology. 2003;61(4):791-796. doi:10.1016/s0090-4295(02)02548-7

McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387–2398. doi:10.1056/NEJMoa030656 | PubMed

Pareek G, Shevchuk M, Armenakas NA, Vasovic L, Hochberg DA, Basillote JB, Fracchia JA. The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. J Urol. 2003 Jan;169(1):20-3. doi:10.1097/01.ju.0000039923.75777.91 | PubMed

Roehrborn CG, Lee M, Meehan A, Waldstreicher J, Group PS. Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia. Urology. 2003;62(5):894-899. doi:10.1016/s0090-4295(03)00661-7

Sadeghi-Nejad H, Sherman N, Lue J. Comparison of finasteride and alpha-blockers as independent risk factors for erectile dysfunction. Int J Clin Pract. 2003;57(6):484-487. PubMed

🐀 Shen ZJ, Zhou XL, Lu YL, Chen ZD. Effect of androgen deprivation on penile ultrastructure. Asian J Androl. 2003 Mar;5(1):33-6. Abstract | Full text | PubMed

Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215-224. doi:10.1056/NEJMoa030660 | PubMed

Thompson IM, Klein EA, Lippman SM, Coltman CA, Djavan B. Prevention of prostate cancer with finasteride: US/European perspective. Eur Urol. 2003;44(6):650-655. doi:10.1016/j.eururo.2003.11.001

Wessells H, Roy J, Bannow J, et al. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology. 2003;61(3):579-584. doi:10.1016/s0090-4295(02)02401-9

Whiting DA, Olsen EA, Savin R, et al. Efficacy and tolerability of finasteride 1 mg in men aged 41 to 60 years with male pattern hair loss. Eur J Dermatol. 2003;13(2):150-160. PubMed

2002

↑ back to top

📚 Edwards JE, Moore RA. Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials. BMC Urol. 2002;2:14. doi:10.1186/1471-2490-2-14

Ferrando J, Grimalt R, Alsina M, Bulla F, Manasievska E. Unilateral gynecomastia induced by treatment with 1 mg of oral finasteride. Arch Dermatol. 2002;138(4):543‐544. doi:10.1001/archderm.138.4.543 | PubMed

Finasteride Male Pattern Hair Loss Study Group. Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol. 2002 Jan-Feb;12(1):38-49. PubMed

Häggström S, Tørring N, Møller K, et al. Effects of finasteride on vascular endothelial growth factor. Scand J Urol Nephrol. 2002. DOI • PubMed

🐀 Huynh H. Induction of apoptosis in rat ventral prostate by finasteride is associated with alteration in MAP kinase pathways and Bcl-2 related family of proteins. Int J Oncol. 2002;20(6):1297-1303. PubMed

Leliefeld HH, Stoevelaar HJ, McDonnell J. Sexual function before and after various treatments for symptomatic benign prostatic hyperplasia. BJU Int. 2002;89(3):208-213. doi:10.1046/j.1464-4096.2001.01817.x

Price VH, Menefee E, Sanchez M, Ruane P, Kaufman KD. Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg, daily. J Am Acad Dermatol. 2002;46(4):517–523. doi:10.1067/mjd.2002.120537 | PubMed

🐀 Rhoden EL, Gobbi D, Menti E, Rhoden C, Telöken C. Effects of the chronic use of finasteride on testicular weight and spermatogenesis in Wistar rats. BJU Int. 2002 Jun;89(9):961-3. doi:10.1046/j.1464-410x.2002.02785.x | PubMed

2001

↑ back to top

🐀 Dadras SS, Cai X, Abasolo I, Wang Z. Inhibition of 5alpha-reductase in rat prostate reveals differential regulation of androgen-response gene expression by testosterone and dihydrotestosterone. Gene Expr. 2001;9(4-5):183–194. doi:10.3727/000000001783992551 | PubMed

Kaplan SA. 5alpha-reductase inhibitors: what role should they play?. Urology. 2001;58(6 Suppl 1):65–70. doi:10.1016/s0090-4295(01)01347-4 | PubMed

Kaplan SA, Holtgrewe HL, Bruskewitz R, et al. Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia. Urology. 2001;57(6):1073–1077. doi:10.1016/s0090-4295(01)00985-2 | PubMed

O’Leary MP. Quality of life and sexuality: methodological aspects. Eur Urol. 2001;40 Suppl 3:13-18. doi:10.1159/000049886

Pole M, Koren G. Finasteride. Does it affect spermatogenesis and pregnancy?. Can Fam Physician. 2001;47:2469–2470. PMC full text | PubMed

Schulman C. Impact of treatment of BPH on sexuality. Prostate Cancer Prostatic Dis. 2001;4(S1):S12-S16. doi:10.1038/sj.pcan.4500541

Stoevelaar HJ, McDonnell J. Changing therapeutic regimens in benign prostatic hyperplasia. Clinical and economic considerations. Pharmacoeconomics. 2001;19(2):131-153. doi:10.2165/00019053-200119020-00003 | PubMed

Tosti A, Piraccini BM, Soli M. Evaluation of sexual function in subjects taking finasteride for the treatment of androgenetic alopecia. J Eur Acad Dermatol Venereol. 2001;15(5):418-421. doi:10.1046/j.1468-3083.2001.00315.x | PubMed

Wise GJ, Md EO. Hormonal treatment of patients with benign prostatic hyperplasia: pros and cons. Curr Urol Rep. 2001;2(4):285-291. doi:10.1007/s11934-001-0065-1

2000

↑ back to top

Clifford GM, Farmer RD. Medical therapy for benign prostatic hyperplasia: a review of the literature. Eur Urol. 2000;38(1):2-19. doi:10.1159/000020246

Krenzer KL, Dana MR, Ullman MD, Cermak JM, Tolls DB, Evans JE, Sullivan DA. Effect of androgen deficiency on the human meibomian gland and ocular surface. J Clin Endocrinol Metab. 2000 Dec;85(12):4874-82. doi:10.1210/jcem.85.12.7072 | PubMed

Van Neste D, Fuh V, Sanchez-Pedreno P, et al. Finasteride increases anagen hair in men with androgenetic alopecia. Br J Dermatol. 2000;143(4):804-810. doi:10.1046/j.1365-2133.2000.03780.x | PubMed

For older papers see Early research (1974–1999)